TELA on Nasdaq

TELA Bio, Inc.

We are a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with PRO DEX INC, Sight Sciences, Inc. or IRADIMED CORP, or pick any stock.

  • TickerTELA on Nasdaq1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersMalvern, Pennsylvania1
  • Incorporated inDE2
  • Business address1 Great Valley Parkway, Suite 24, Malvern, Pa 193552
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

We are a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Our growing product portfolio is purposefully designed to leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. We are committed to delivering our advanced technologies with a strong economic value proposition to assist surgeons and institutions in providing next-generation soft-tissue repair solutions to more patients worldwide.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

67.7%Gross margin4
-42.0%Operating margin4
-48.4%Net margin4
15.8%Revenue growth, 20254
-615.1%Return on equity4
8.82×Debt to equity4
-$28.7MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development11¢$9.2M
  • Other costs88¢$70.8M
  • Income tax0¢$230.0K

Out of $80.3M in revenue.4 The company lost money this year.

Financial statements

Revenue56784$80.3M in 2025+420% since 2019
0$25.0M$50.0M$75.0M$100.0M2019: $15.4M$15.4M20192020: $18.2M$18.2M2020+18%2021: $29.5M$29.5M2021+62%2022: $41.4M$41.4M2022+41%2023: $58.5M$58.5M2023+41%2024: $69.3M$69.3M2024+19%2025: $80.3M$80.3M2025+16%
Gross profit56784$54.3M in 2025+486% since 2019
0$20.0M$40.0M$60.0M2019: $9.3M$9.3M20192020: $11.2M$11.2M2020+21%2021: $18.8M$18.8M2021+67%2022: $27.0M$27.0M2022+44%2023: $40.1M$40.1M2023+48%2024: $46.5M$46.5M2024+16%2025: $54.3M$54.3M2025+17%
Operating income56784-$33.8M in 2025+76% since 2019
-$60.0M-$40.0M-$20.0M02019: -$19.2M-$19.2M20192020: -$25.3M-$25.3M2020+32%2021: -$29.5M-$29.5M2021+17%2022: -$39.0M-$39.0M2022+32%2023: -$44.1M-$44.1M2023+13%2024: -$34.1M-$34.1M2024−23%2025: -$33.8M-$33.8M2025−1%
Net income56784-$38.8M in 2025+73% since 2019
-$60.0M-$40.0M-$20.0M02019: -$22.4M-$22.4M20192020: -$28.8M-$28.8M2020+28%2021: -$33.3M-$33.3M2021+16%2022: -$44.3M-$44.3M2022+33%2023: -$46.7M-$46.7M2023+5%2024: -$37.8M-$37.8M2024−19%2025: -$38.8M-$38.8M2025+3%

Every line of the income statement as filed: the last 3 fiscal years, latest first.4

Period ending2025-12-312024-12-312023-12-31
Revenue$80.3M$69.3M$58.5M
Cost of revenue (excluding amortization of intangible assets)$25.6M$22.4M$18.0M
Amortization of intangible assets$380.0K$380.0K$380.0K
Gross profit$54.3M$46.5M$40.1M
Sales and marketing$63.2M$64.6M$59.7M
General and administrative$15.7M$14.7M$14.9M
Research and development$9.2M$8.8M$9.6M
Total operating expenses$88.1M$88.2M$84.2M
Gain on sale of product line$7.6M
Loss from operations-$33.8M-$34.1M-$44.1M
Interest expense-$5.2M-$5.3M-$5.2M
Loss on extinguishment of debt-$888.0K
Other income$1.3M$1.4M$2.6M
Total other expense, net-$4.8M-$3.9M-$2.6M
Loss before income tax (expense) benefit-$38.6M-$38.0M-$46.7M
Income tax (expense) benefit-$230.0K$144.0K
Net loss-$38.8M-$37.8M-$46.7M
Net loss per common share, basic (in dollars per share)-$0.83-$1.33-$2.04
Net loss per common share, diluted (in dollars per share)-$0.83-$1.33-$2.04
Weighted average common shares outstanding, basic (in shares)46.9M shares28.5M shares22.9M shares
Weighted average common shares outstanding, diluted (in shares)46.9M shares28.5M shares22.9M shares
Foreign currency translation adjustment$1.0K-$1.0K-$59.0K
Comprehensive loss-$38.8M-$37.8M-$46.7M

Compare TELA Bio, Inc. with another company

Leadership

Who has led TELA Bio, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Antony Koblish2019–2026
  2. Heather C. Getz2026–now

President

  1. Jeffrey Blizard2025–now

Chief financial officer

  1. Nora Brennan2019–2021
  2. Roberto Cuca2021–now

Chief operating officer

  1. Roberto Cuca2021–now
20202025
Board members and other officers (25)

Timeline

  1. Aug 5, 2026New chief executive Heather C. Getz becomes CEO12
  2. Nov 7, 2019New chief executive Antony Koblish becomes CEO13

Filings

365 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 62 major events, 193 insider forms, 47 large holders, 43 other. The latest 20:

  1. Oct 8, 20268-K EDGAR
  2. Oct 6, 20268-K EDGAR
  3. Oct 5, 20268-K EDGAR
  4. Sep 29, 20268-K EDGAR
  5. Sep 18, 20264 EDGAR
  6. Sep 18, 20268-K EDGAR
  7. Sep 16, 20264 EDGAR
  8. Sep 14, 2026DEF 14A EDGAR
  9. Sep 4, 2026PRE 14A EDGAR
  10. Aug 31, 20268-K EDGAR
  11. Aug 19, 20264 EDGAR
  12. Aug 17, 20264 EDGAR
  13. Aug 14, 2026SCHEDULE 13G/A EDGAR
  14. Aug 14, 2026SCHEDULE 13G/A EDGAR
  15. Aug 13, 20268-K/A EDGAR
  16. Aug 11, 2026S-8 EDGAR
  17. Aug 11, 202610-Q EDGAR
  18. Aug 11, 2026SCHEDULE 13G EDGAR
  19. Aug 10, 20268-K EDGAR
  20. Aug 5, 20264 EDGAR

The 365 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

154 open-market trades by officers, directors and large owners since October 2021: 148 buys and 6 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 17, 2026Capper Joseph HDirectorBuy25,000$1.22$30.5KForm 4
Sep 16, 2026Capper Joseph HDirectorBuy50,000$1.17$58.5KForm 4
Sep 15, 2026Capper Joseph HDirectorBuy50,000$1.06$53.0KForm 4
Sep 14, 2026Capper Joseph HDirectorBuy25,000$1.02$25.5KForm 4
Aug 17, 2026Getz Heather CChief Executive OfficerBuy12,500$0.66$8.2KForm 4
Aug 14, 2026Getz Heather CChief Executive OfficerBuy15,000$0.70$10.5KForm 4
Nov 17, 2025EW Healthcare Partners Fund 2-UGP, LLC10% ownerBuy3,604,000$1.11$4.0MForm 4
Oct 24, 2024Cuca RobertoCOO and CFOBuy64,444$2.25$145.0KForm 4
Oct 24, 2024Talmo PaulChief Technology OfficerBuy22,222$2.25$50.0KForm 4
Oct 24, 2024KOBLISH ANTONYChief Executive OfficerBuy88,888$2.25$200.0KForm 4
Oct 24, 2024Firestone Gregory A.Chief Business OfficerBuy6,666$2.25$15.0KForm 4
Jul 2, 2024ORBIMED ADVISORS LLC10% ownerSale36,600$4.54$166.2KForm 4
Jul 1, 2024ORBIMED ADVISORS LLC10% ownerSale13,700$4.68$64.1KForm 4
Jun 28, 2024ORBIMED ADVISORS LLC10% ownerSale378,000$4.74$1.8MForm 4
Dec 5, 2023Firestone Gregory A.Chief Business OfficerBuy2,600$5.65$14.7KForm 4
Nov 14, 2023Cuca RobertoCOO and CFOBuy10,000$4.49$44.9KForm 4
Nov 14, 2023KOBLISH ANTONYChief Executive OfficerBuy11,000$4.54$49.9KForm 4
Apr 21, 2023ORBIMED ADVISORS LLC10% ownerSale27,700$9.41$260.7KForm 4
Apr 20, 2023ORBIMED ADVISORS LLC10% ownerSale28,300$9.43$266.9KForm 4
Apr 19, 2023ORBIMED ADVISORS LLC10% ownerSale136,000$9.30$1.3MForm 4

All 154 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 45. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Nantahala Capital Management, LLC11,788,228$8.8M0.3%+6,644,114
Essex Woodlands Management, Inc.7,714,709$5.8M2.3%No change
Stonepine Capital Management, LLC2,662,427$2.0M1.5%+45,175
Silverarc Capital Management, LLC2,137,201$1.6M0.2%−122,111
Vanguard Capital Management LLC1,568,218$1.2M0.0%+27,594
DAFNA Capital Management LLC1,441,029$1.1M0.2%No change
Perkins Capital Management Inc1,375,042$1.0M0.8%−43,286
Sio Capital Management, LLC636,300$477.2K0.1%No change
WealthTrust Axiom LLC457,734$343.3K0.1%+80,796
Geode Capital Management, LLC389,223$292.0K0.0%−65,836
BlackRock, Inc.374,516$280.9K0.0%−91,298
Vanguard Fiduciary Trust Co213,138$159.9K0.0%+1,476
Up Strategic Wealth Investment Advisors LLC99,888$91.4K0.1%No change
Embree Financial Group90,906$68.2K0.0%−27,272
Northern Trust Corp74,790$56.1K0.0%−99,608
Raymond James Financial Inc67,700$50.8K0.0%+18,000
State Street Corp63,383$47.5K0.0%No change
Renaissance Technologies LLC58,100$43.6K0.0%+5,500
PNC Financial Services Group, Inc.53,612$40.2K0.0%No change
Destiny Wealth Partners, LLC52,500$38.3K0.0%No change
Ducere Wealth Management LLC51,000$38.2K0.0%+10,000
Jane Street Group, LLC49,245$36.9K0.0%New
UBS Group AG33,466$25.1K0.0%−1,026,058
XTX Topco Ltd29,558$22.2K0.0%+14,385
TD Waterhouse Canada Inc.23,000$16.6K0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53